Company / Capital Expenditures
Solid Biosciences Inc. Capital Expenditures History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$899.0K
FY2022
5-year range
$392.0K / $7.8M
FY2018-FY2022
Trend
-79.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $8M to $899,000 over the past 2 years.
Based on SEC 10-K filings.
$899,000 in FY2022 with a 3-year CAGR of -26.6%.
Declined from $8M to $899,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -26.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -26.6%, indicating a declining trend.
- In FY2022, capital expenditures decreased 79.5% year-over-year.
- Peak capital expenditures was recorded in FY2020.
- Lowest capital expenditures in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $899.0K | -79.5% |
| FY2021 | $4.4M | -43.6% |
| FY2020 | $7.8M | +241.7% |
| FY2019 | $2.3M | +480.6% |
| FY2018 | $392.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026